Kyntra Bio (KYNB) Amortizatization of Intangibles (2014 - 2026)
Kyntra Bio (KYNB) posted Amortizatization of Intangibles of $183000.0 for Q1 2026, up 150.68% sequentially from $73000.0 in Q4 2025, and up 18200.0% YoY from N/an in Q1 2025.
Kyntra Bio (KYNB) Amortizatization of Intangibles (2014 - 2026) Analysis & Trends
Kyntra Bio has reported Amortizatization of Intangibles for 13 years, with the latest figure at $183000.0 in Q1 2026.
- Quarterly Amortizatization of Intangibles rose 18200.0% year-over-year to $183000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $254000.0 (up 775.86% YoY) and the FY2025 annual result came in at $72000.0, up 89.47% from the prior year.
- Amortizatization of Intangibles climbed to $183000.0 in Q1 2026 per KYNB's latest filing, from $73000.0 in the prior quarter.
- Over five years, Amortizatization of Intangibles peaked at $2.4 million in Q4 2022 and troughed at -$1.7 million in Q3 2024.
- A 5-year average of $76000.0 and a median of $10000.0 in 2023 frame the typical range for Amortizatization of Intangibles.
- The sharpest annual moves came in 2022 and 2026: Amortizatization of Intangibles slumped 608.4% in 2022, then soared 18200.0% in 2026.
- Over 5 years, Amortizatization of Intangibles stood at $2.4 million in 2022, then sank by 99.59% to $10000.0 in 2023, then changed by 0.0% to $10000.0 in 2024, then soared by 630.0% to $73000.0 in 2025, then jumped by 150.68% to $183000.0 in 2026.
- According to Business Quant data, Amortizatization of Intangibles over the past three periods registered $183000.0, $73000.0, and -$19000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 678,000.00 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Kyntra Bio | 30.42 Mn | 30.42 Mn | 1.47 Mn | 98,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 98,000.00 |
| Jun 30, 2026 | 98,000.00 |
| Mar 31, 2026 | 183,000.00 |
| Mar 31, 2026 | 183,000.00 |
| Dec 31, 2025 | 73,000.00 |
| Dec 31, 2025 | 73,000.00 |
| Sep 30, 2025 | -19,000.00 |
| Sep 30, 2025 | -19,000.00 |
| Jun 30, 2025 | 17,000.00 |
| Jun 30, 2025 | 17,000.00 |
| Mar 31, 2025 | 1,000.00 |
| Mar 31, 2025 | 1,000.00 |
| Dec 31, 2024 | 10,000.00 |
| Dec 31, 2024 | 10,000.00 |
| Sep 30, 2024 | -1.65 Mn |
| Sep 30, 2024 | -1.65 Mn |
| Jun 30, 2024 | 1.67 Mn |
| Jun 30, 2024 | 1.67 Mn |
| Mar 31, 2024 | 10,000.00 |
| Mar 31, 2024 | 10,000.00 |